Conventional strategies such as angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-II-receptor blockers (ARBs) are renoprotective and reduce the risk of end-stage renal disease (ERSD)19. Here, ACE is linked to chronic kidney disease.